In patients with T-cell non-Hodgkin lymphoma (NHL) undergoing hematopoietic cell transplantation (HCT), delaying either autologous or allogeneic HCT results in significantly worse outcomes, according to an analysis of 241 transplants reported to CIBMTR (Center for International Blood and Marrow Transplant Research). Patients transplanted after more than two lines of prior therapy had significantly higher risks of overall mortality (hazard ratio [HR], 5.02; 95% CI, 2.15-11.72; p<0.001), relapse (HR, 3.00; 95% CI, 1.56-5.71; p<0.001), and non-relapse mortality (HR, 7.04; 95% CI, 1.68-29.61; p=0.008). The researchers concluded that "... both toxicity and efficacy are optimized by fewer prior chemotherapy regimens, and transplantation is most beneficial when offered as part of first- or second-line therapy."
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Earlier HCT Improves Outcomes in T-cell NHL
Aug 2013